Page 15 - Kirin Holdings Case Study

The revenue amounts of Kirin Brewery, Mercian

Corporation, and Kyowa Hakko Kirin include sales tax on
liquor. Diagram 3; Source: Kirin Report 2018 (4)

However, in November 2018 Kirin Holdings announced, a

shift in its core business strategy from beverages to “health

and illness-preventing” solutions. It was planning a global

expansion of products that used its proprietary lactic acid
bacteria technology, which it believed could prevent

illnesses like the common cold and influenza. The objective

was to achieve a tripling of revenue growth in Kirin Group’s
health care division to about 100 billion yen ($880 million).

(1)

“Kyowa Hakko Kirin Group provides high-quality products

and services in the pharmaceutical and biochemical fields to

contribute to the health and well-being of people around
the world.

At the Group's core is Kyowa Hakko Kirin (KHK), a rapidly

evolving global specialty pharmaceutical company (GSP).
KHK develops innovative ethical drugs, driven by state-of-

the-art biotechnologies, focusing on nephrology, oncology,

immunology/allergy, and neurology. Our clinical pipeline

and product portfolio contain four main modalities: next-
generation therapeutic antibodies, new types of small

molecule drugs, nucleic acid drugs, and regenerative

therapeutics.” Yoshinori Isozaki, CEO & President, Kirin Holdings (1)